177 related articles for article (PubMed ID: 32126512)
1. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P
Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcal meningoencephalitis in an IgG
Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
[TBL] [Abstract][Full Text] [Related]
4. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
5. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
Grebenciucova E; Reder AT; Bernard JT
Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
8. Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod.
Behle V; Wobser M; Goebeler M; Stoevesandt J
Mult Scler; 2016 Jun; 22(7):969-71. PubMed ID: 26860987
[TBL] [Abstract][Full Text] [Related]
9. Ventricular tachycardia after initiation of fingolimod.
Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
[TBL] [Abstract][Full Text] [Related]
10. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
11. [Infections and fingolimod].
Cervera C
Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
14. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
16. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
[TBL] [Abstract][Full Text] [Related]
17. Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.
Ong S; Kibbler J; Maxwell G; Steer J
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171639
[TBL] [Abstract][Full Text] [Related]
18. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
19. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
